Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis

Objectives To assess any benefit or harm, we conducted a systematic review of randomised clinical trials (RCTs) allocating adults to dexmedetomidine versus placebo/no intervention for the prevention of delirium in intensive care or post‐operative care units. Data Sources We searched Medline, Embase,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta anaesthesiologica Scandinavica 2023-04, Vol.67 (4), p.382-411
Hauptverfasser: Maagaard, Mathias, Barbateskovic, Marija, Andersen‐Ranberg, Nina C., Kronborg, Jonas R., Chen, Ya‐Xin, Xi, Huan‐Huan, Perner, Anders, Wetterslev, Jørn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 411
container_issue 4
container_start_page 382
container_title Acta anaesthesiologica Scandinavica
container_volume 67
creator Maagaard, Mathias
Barbateskovic, Marija
Andersen‐Ranberg, Nina C.
Kronborg, Jonas R.
Chen, Ya‐Xin
Xi, Huan‐Huan
Perner, Anders
Wetterslev, Jørn
description Objectives To assess any benefit or harm, we conducted a systematic review of randomised clinical trials (RCTs) allocating adults to dexmedetomidine versus placebo/no intervention for the prevention of delirium in intensive care or post‐operative care units. Data Sources We searched Medline, Embase, CENTRAL and other databases. The last search was 9 April 2022. Data Extraction Literature screening, data extraction and risk of bias volume 2 assessments were performed independently and in duplicate. Primary outcomes were occurrences of serious adverse events (SAEs), delirium and all‐cause mortality. We used meta‐analysis, Trial Sequential Analysis, and GRADE (Grading Recommendations Assessment, Development and Evaluation). Data Synthesis Eighty‐one RCTs (15,745 patients) provided data for our primary outcomes. Results from trials at low risk of bias showed that dexmedetomidine may reduce the occurrence of the most frequently reported SAEs (relative risk [RR] 0.69; 95% CI 0.43–1.09), cumulated SAEs (RR 0.70; 95% CI 0.52–0.95) and the occurrence of delirium (RR 0.62; 95% CI 0.43–0.89). The certainty of evidence was very low for delirium. Mortality was very low in trials at low risk of bias (0.4% in the dexmedetomidine groups and 1.0% in the control groups) and meta‐analysis did not provide conclusive evidence that dexmedetomidine may result in lower or higher all‐cause mortality (RR 0.47; 95% CI 0.18–1.21). There was a lack of information from trial results at low risk of bias for all primary outcomes. Conclusions Trial results at low risk of bias showed that dexmedetomidine might reduce occurrences of SAEs and delirium, while no conclusive evidence was found for effects on all‐cause mortality. The certainty of evidence ranged from very low for occurrence of delirium to low for the remaining outcomes.
doi_str_mv 10.1111/aas.14208
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2770120552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789183970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-fd79001bfacacf3cbbd16bb64b8e0ec733a512430be6fd55c270f22f709233be3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_kzhhN2r5kyqxaFlHjn2jukrsYDudzo5H6CMinoSbzoAEEt5cW_fzucc-hLzk7ITjOtU6nfC1YPUjsuKyaYqqVNVjsmKM8aLkShyRZynd4FGum-YpOZKVYkLVbEV-nMPdCBZyGJ11HmgfIs3XQKcIt-CzC56GnloYXHTzSJ2n2s5DTlhGlzNYmsPDBecz-ORugRodgc7eZYpaU0j55_f7MEHU-a_uO7qhaZcyjNgwFOc52C7DovYW7STUNoPzzuiB5uj0kOjW5Ws6QtYoqb0edsmhE2_p1dKnl_BtXkzjdnPoPidPerwJLw71mHz98P7q7FNx8eXj57PNRWFkXddFb1WDv9X12mjTS9N1llddV627GhgYJaUuuVhL1kHV27I0QrFeiF6xRkjZgTwmb_a6UwxoIuUWX2BgGLSHMKdWKMW4YGUpEH39D3oT5oh-F6pueC0bxZB6u6dMDClF6NspulHHXctZu8TeYuztQ-zIvjoozh2m-Yf8nTMCp3tg6wbY_V-p3Wwu95K_AKc6vsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789183970</pqid></control><display><type>article</type><title>Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Maagaard, Mathias ; Barbateskovic, Marija ; Andersen‐Ranberg, Nina C. ; Kronborg, Jonas R. ; Chen, Ya‐Xin ; Xi, Huan‐Huan ; Perner, Anders ; Wetterslev, Jørn</creator><creatorcontrib>Maagaard, Mathias ; Barbateskovic, Marija ; Andersen‐Ranberg, Nina C. ; Kronborg, Jonas R. ; Chen, Ya‐Xin ; Xi, Huan‐Huan ; Perner, Anders ; Wetterslev, Jørn</creatorcontrib><description>Objectives To assess any benefit or harm, we conducted a systematic review of randomised clinical trials (RCTs) allocating adults to dexmedetomidine versus placebo/no intervention for the prevention of delirium in intensive care or post‐operative care units. Data Sources We searched Medline, Embase, CENTRAL and other databases. The last search was 9 April 2022. Data Extraction Literature screening, data extraction and risk of bias volume 2 assessments were performed independently and in duplicate. Primary outcomes were occurrences of serious adverse events (SAEs), delirium and all‐cause mortality. We used meta‐analysis, Trial Sequential Analysis, and GRADE (Grading Recommendations Assessment, Development and Evaluation). Data Synthesis Eighty‐one RCTs (15,745 patients) provided data for our primary outcomes. Results from trials at low risk of bias showed that dexmedetomidine may reduce the occurrence of the most frequently reported SAEs (relative risk [RR] 0.69; 95% CI 0.43–1.09), cumulated SAEs (RR 0.70; 95% CI 0.52–0.95) and the occurrence of delirium (RR 0.62; 95% CI 0.43–0.89). The certainty of evidence was very low for delirium. Mortality was very low in trials at low risk of bias (0.4% in the dexmedetomidine groups and 1.0% in the control groups) and meta‐analysis did not provide conclusive evidence that dexmedetomidine may result in lower or higher all‐cause mortality (RR 0.47; 95% CI 0.18–1.21). There was a lack of information from trial results at low risk of bias for all primary outcomes. Conclusions Trial results at low risk of bias showed that dexmedetomidine might reduce occurrences of SAEs and delirium, while no conclusive evidence was found for effects on all‐cause mortality. The certainty of evidence ranged from very low for occurrence of delirium to low for the remaining outcomes.</description><identifier>ISSN: 0001-5172</identifier><identifier>EISSN: 1399-6576</identifier><identifier>DOI: 10.1111/aas.14208</identifier><identifier>PMID: 36702780</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Adults ; Bias ; Clinical trials ; Critical Care ; Data search ; Delirium ; Delirium - prevention &amp; control ; dexmedetomidine ; Dexmedetomidine - therapeutic use ; Hospitalization ; Humans ; Intensive care ; intensive care unit ; Intensive Care Units ; Mental disorders ; Meta-analysis ; Mortality ; post‐operative ; Prevention ; Risk ; Sequential analysis ; Systematic review</subject><ispartof>Acta anaesthesiologica Scandinavica, 2023-04, Vol.67 (4), p.382-411</ispartof><rights>2023 The Authors. published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-fd79001bfacacf3cbbd16bb64b8e0ec733a512430be6fd55c270f22f709233be3</citedby><cites>FETCH-LOGICAL-c3888-fd79001bfacacf3cbbd16bb64b8e0ec733a512430be6fd55c270f22f709233be3</cites><orcidid>0000-0003-1967-1106 ; 0000-0001-7778-1771 ; 0000-0002-9037-7295 ; 0000-0002-0804-1064 ; 0000-0001-8566-3660 ; 0000-0002-4668-0123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faas.14208$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faas.14208$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36702780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maagaard, Mathias</creatorcontrib><creatorcontrib>Barbateskovic, Marija</creatorcontrib><creatorcontrib>Andersen‐Ranberg, Nina C.</creatorcontrib><creatorcontrib>Kronborg, Jonas R.</creatorcontrib><creatorcontrib>Chen, Ya‐Xin</creatorcontrib><creatorcontrib>Xi, Huan‐Huan</creatorcontrib><creatorcontrib>Perner, Anders</creatorcontrib><creatorcontrib>Wetterslev, Jørn</creatorcontrib><title>Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis</title><title>Acta anaesthesiologica Scandinavica</title><addtitle>Acta Anaesthesiol Scand</addtitle><description>Objectives To assess any benefit or harm, we conducted a systematic review of randomised clinical trials (RCTs) allocating adults to dexmedetomidine versus placebo/no intervention for the prevention of delirium in intensive care or post‐operative care units. Data Sources We searched Medline, Embase, CENTRAL and other databases. The last search was 9 April 2022. Data Extraction Literature screening, data extraction and risk of bias volume 2 assessments were performed independently and in duplicate. Primary outcomes were occurrences of serious adverse events (SAEs), delirium and all‐cause mortality. We used meta‐analysis, Trial Sequential Analysis, and GRADE (Grading Recommendations Assessment, Development and Evaluation). Data Synthesis Eighty‐one RCTs (15,745 patients) provided data for our primary outcomes. Results from trials at low risk of bias showed that dexmedetomidine may reduce the occurrence of the most frequently reported SAEs (relative risk [RR] 0.69; 95% CI 0.43–1.09), cumulated SAEs (RR 0.70; 95% CI 0.52–0.95) and the occurrence of delirium (RR 0.62; 95% CI 0.43–0.89). The certainty of evidence was very low for delirium. Mortality was very low in trials at low risk of bias (0.4% in the dexmedetomidine groups and 1.0% in the control groups) and meta‐analysis did not provide conclusive evidence that dexmedetomidine may result in lower or higher all‐cause mortality (RR 0.47; 95% CI 0.18–1.21). There was a lack of information from trial results at low risk of bias for all primary outcomes. Conclusions Trial results at low risk of bias showed that dexmedetomidine might reduce occurrences of SAEs and delirium, while no conclusive evidence was found for effects on all‐cause mortality. The certainty of evidence ranged from very low for occurrence of delirium to low for the remaining outcomes.</description><subject>Adult</subject><subject>Adults</subject><subject>Bias</subject><subject>Clinical trials</subject><subject>Critical Care</subject><subject>Data search</subject><subject>Delirium</subject><subject>Delirium - prevention &amp; control</subject><subject>dexmedetomidine</subject><subject>Dexmedetomidine - therapeutic use</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Intensive care</subject><subject>intensive care unit</subject><subject>Intensive Care Units</subject><subject>Mental disorders</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>post‐operative</subject><subject>Prevention</subject><subject>Risk</subject><subject>Sequential analysis</subject><subject>Systematic review</subject><issn>0001-5172</issn><issn>1399-6576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_kzhhN2r5kyqxaFlHjn2jukrsYDudzo5H6CMinoSbzoAEEt5cW_fzucc-hLzk7ITjOtU6nfC1YPUjsuKyaYqqVNVjsmKM8aLkShyRZynd4FGum-YpOZKVYkLVbEV-nMPdCBZyGJ11HmgfIs3XQKcIt-CzC56GnloYXHTzSJ2n2s5DTlhGlzNYmsPDBecz-ORugRodgc7eZYpaU0j55_f7MEHU-a_uO7qhaZcyjNgwFOc52C7DovYW7STUNoPzzuiB5uj0kOjW5Ws6QtYoqb0edsmhE2_p1dKnl_BtXkzjdnPoPidPerwJLw71mHz98P7q7FNx8eXj57PNRWFkXddFb1WDv9X12mjTS9N1llddV627GhgYJaUuuVhL1kHV27I0QrFeiF6xRkjZgTwmb_a6UwxoIuUWX2BgGLSHMKdWKMW4YGUpEH39D3oT5oh-F6pueC0bxZB6u6dMDClF6NspulHHXctZu8TeYuztQ-zIvjoozh2m-Yf8nTMCp3tg6wbY_V-p3Wwu95K_AKc6vsw</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Maagaard, Mathias</creator><creator>Barbateskovic, Marija</creator><creator>Andersen‐Ranberg, Nina C.</creator><creator>Kronborg, Jonas R.</creator><creator>Chen, Ya‐Xin</creator><creator>Xi, Huan‐Huan</creator><creator>Perner, Anders</creator><creator>Wetterslev, Jørn</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1967-1106</orcidid><orcidid>https://orcid.org/0000-0001-7778-1771</orcidid><orcidid>https://orcid.org/0000-0002-9037-7295</orcidid><orcidid>https://orcid.org/0000-0002-0804-1064</orcidid><orcidid>https://orcid.org/0000-0001-8566-3660</orcidid><orcidid>https://orcid.org/0000-0002-4668-0123</orcidid></search><sort><creationdate>202304</creationdate><title>Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis</title><author>Maagaard, Mathias ; Barbateskovic, Marija ; Andersen‐Ranberg, Nina C. ; Kronborg, Jonas R. ; Chen, Ya‐Xin ; Xi, Huan‐Huan ; Perner, Anders ; Wetterslev, Jørn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-fd79001bfacacf3cbbd16bb64b8e0ec733a512430be6fd55c270f22f709233be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Bias</topic><topic>Clinical trials</topic><topic>Critical Care</topic><topic>Data search</topic><topic>Delirium</topic><topic>Delirium - prevention &amp; control</topic><topic>dexmedetomidine</topic><topic>Dexmedetomidine - therapeutic use</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Intensive care</topic><topic>intensive care unit</topic><topic>Intensive Care Units</topic><topic>Mental disorders</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>post‐operative</topic><topic>Prevention</topic><topic>Risk</topic><topic>Sequential analysis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maagaard, Mathias</creatorcontrib><creatorcontrib>Barbateskovic, Marija</creatorcontrib><creatorcontrib>Andersen‐Ranberg, Nina C.</creatorcontrib><creatorcontrib>Kronborg, Jonas R.</creatorcontrib><creatorcontrib>Chen, Ya‐Xin</creatorcontrib><creatorcontrib>Xi, Huan‐Huan</creatorcontrib><creatorcontrib>Perner, Anders</creatorcontrib><creatorcontrib>Wetterslev, Jørn</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta anaesthesiologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maagaard, Mathias</au><au>Barbateskovic, Marija</au><au>Andersen‐Ranberg, Nina C.</au><au>Kronborg, Jonas R.</au><au>Chen, Ya‐Xin</au><au>Xi, Huan‐Huan</au><au>Perner, Anders</au><au>Wetterslev, Jørn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis</atitle><jtitle>Acta anaesthesiologica Scandinavica</jtitle><addtitle>Acta Anaesthesiol Scand</addtitle><date>2023-04</date><risdate>2023</risdate><volume>67</volume><issue>4</issue><spage>382</spage><epage>411</epage><pages>382-411</pages><issn>0001-5172</issn><eissn>1399-6576</eissn><abstract>Objectives To assess any benefit or harm, we conducted a systematic review of randomised clinical trials (RCTs) allocating adults to dexmedetomidine versus placebo/no intervention for the prevention of delirium in intensive care or post‐operative care units. Data Sources We searched Medline, Embase, CENTRAL and other databases. The last search was 9 April 2022. Data Extraction Literature screening, data extraction and risk of bias volume 2 assessments were performed independently and in duplicate. Primary outcomes were occurrences of serious adverse events (SAEs), delirium and all‐cause mortality. We used meta‐analysis, Trial Sequential Analysis, and GRADE (Grading Recommendations Assessment, Development and Evaluation). Data Synthesis Eighty‐one RCTs (15,745 patients) provided data for our primary outcomes. Results from trials at low risk of bias showed that dexmedetomidine may reduce the occurrence of the most frequently reported SAEs (relative risk [RR] 0.69; 95% CI 0.43–1.09), cumulated SAEs (RR 0.70; 95% CI 0.52–0.95) and the occurrence of delirium (RR 0.62; 95% CI 0.43–0.89). The certainty of evidence was very low for delirium. Mortality was very low in trials at low risk of bias (0.4% in the dexmedetomidine groups and 1.0% in the control groups) and meta‐analysis did not provide conclusive evidence that dexmedetomidine may result in lower or higher all‐cause mortality (RR 0.47; 95% CI 0.18–1.21). There was a lack of information from trial results at low risk of bias for all primary outcomes. Conclusions Trial results at low risk of bias showed that dexmedetomidine might reduce occurrences of SAEs and delirium, while no conclusive evidence was found for effects on all‐cause mortality. The certainty of evidence ranged from very low for occurrence of delirium to low for the remaining outcomes.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36702780</pmid><doi>10.1111/aas.14208</doi><tpages>30</tpages><orcidid>https://orcid.org/0000-0003-1967-1106</orcidid><orcidid>https://orcid.org/0000-0001-7778-1771</orcidid><orcidid>https://orcid.org/0000-0002-9037-7295</orcidid><orcidid>https://orcid.org/0000-0002-0804-1064</orcidid><orcidid>https://orcid.org/0000-0001-8566-3660</orcidid><orcidid>https://orcid.org/0000-0002-4668-0123</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0001-5172
ispartof Acta anaesthesiologica Scandinavica, 2023-04, Vol.67 (4), p.382-411
issn 0001-5172
1399-6576
language eng
recordid cdi_proquest_miscellaneous_2770120552
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Adults
Bias
Clinical trials
Critical Care
Data search
Delirium
Delirium - prevention & control
dexmedetomidine
Dexmedetomidine - therapeutic use
Hospitalization
Humans
Intensive care
intensive care unit
Intensive Care Units
Mental disorders
Meta-analysis
Mortality
post‐operative
Prevention
Risk
Sequential analysis
Systematic review
title Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T19%3A47%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexmedetomidine%20for%20the%20prevention%20of%20delirium%20in%20adults%20admitted%20to%20the%20intensive%20care%20unit%20or%20post%E2%80%90operative%20care%20unit:%20A%20systematic%20review%20of%20randomised%20clinical%20trials%20with%20meta%E2%80%90analysis%20and%20Trial%20Sequential%20Analysis&rft.jtitle=Acta%20anaesthesiologica%20Scandinavica&rft.au=Maagaard,%20Mathias&rft.date=2023-04&rft.volume=67&rft.issue=4&rft.spage=382&rft.epage=411&rft.pages=382-411&rft.issn=0001-5172&rft.eissn=1399-6576&rft_id=info:doi/10.1111/aas.14208&rft_dat=%3Cproquest_cross%3E2789183970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2789183970&rft_id=info:pmid/36702780&rfr_iscdi=true